

<i>Highly Specialised Technologies (HST)</i>	<i>Date of HST Release</i>	<i>Adherence of local formulary to NICE</i>	
		<i>Included on the Trust Formulary for this indication</i> <i>Yes OR</i> <i>No</i>	<i>Reason provided if "No"</i>
2021-22			
HST18 - Atidarsagene autotemcel for treating metachromatic leukodystrophy	28/03/2022	No	Not applicable to CWFT - not commissioned
HST17 - Odevixibat for treating progressive familial intrahepatic cholestasis	22/02/2022	No	Not applicable to CWFT - not commissioned
HST16 - Givosiran for treating acute hepatic porphyria	24/11/2021	No	Not applicable to CWFT - not commissioned
HST15 - Onasemnogene abeparvovec for treating spinal muscular atrophy	07/07/2021	No	Not applicable to CWFT - not commissioned